Literature DB >> 17186400

Antimicrobial susceptibilities of Campylobacter jejuni isolates from hospitalized children in Athens, Greece, collected during 2004-2005.

Eleni Papavasileiou, Aliki Voyatzi, Konstantina Papavasileiou, Antonia Makri, Ioanna Andrianopoulou, Stylianos Chatzipanagiotou.   

Abstract

A total of 170 Campylobacter jejuni strains isolated from the stool of children with clinical gastroenteritis, aged from 3 months to 14 years, were collected during a two-year period (2004-2005). From the 170 strains 30% were resistant to ciprofloxacin (MIC > or = 4 microg/ml), 55% to tetracycline (MIC > 8 microg/ml), 13% to clindamycin (MIC > or = 8 microg/ml), 4% to ampicillin (MIC > 16 microg/ml), 6% to erythromycin (MIC > or = 8 microg/ml), 4% to coamoxiclav (MIC > or = 16/8 microg/ml) and 0% to gentamicin. Compared to previous reports from Greece, the antimicrobial resistance rates to erythromycin, ampicillin and coamoxiclav remain low, while they are still high for tetracycline and ciprofloxacin. Considering similar reports from many other countries and the high incidence of Campylobacter gastroenteritis worldwide, the value of ciprofloxacin as a first choice drug in the empiric treatment of the infection is questionable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17186400     DOI: 10.1007/s10654-006-9080-3

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  6 in total

1.  Antimicrobial susceptibility patterns of Campylobacter jejuni strains isolated from hospitalized children in Athens, Greece.

Authors:  S Chatzipanagiotou; E Papavasileiou; A Lakumenta; A Makri; C Nicolaou; K Chantzis; S Manganas; N I Legakis
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

2.  Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.

Authors:  Jutta Wagner; Miriam Jabbusch; Martin Eisenblätter; Helmut Hahn; Constanze Wendt; Ralf Ignatius
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

3.  [Susceptibility of Campylobacter jejuni clinical isolates from children to eight antibiotics].

Authors:  J A García-Campos; T Alarcón; D Domingo; M Menéndez-Rivas; M López-Brea
Journal:  Rev Esp Quimioter       Date:  2003-06       Impact factor: 1.553

4.  Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study.

Authors:  P N Gaunt; L J Piddock
Journal:  J Antimicrob Chemother       Date:  1996-04       Impact factor: 5.790

5.  Antimicrobial resistance of Campylobacter jejuni subsp. jejuni strains isolated from humans in 1998 to 2001 in Montréal, Canada.

Authors:  Christiane Gaudreau; Huguette Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

6.  Multidrug resistance in Campylobacter jejuni strains collected from Finnish patients during 1995-2000.

Authors:  Antti J Hakanen; Mirva Lehtopolku; Anja Siitonen; Pentti Huovinen; Pirkko Kotilainen
Journal:  J Antimicrob Chemother       Date:  2003-11-12       Impact factor: 5.790

  6 in total
  3 in total

Review 1.  Antibiotic resistance in Campylobacter: emergence, transmission and persistence.

Authors:  Taradon Luangtongkum; Byeonghwa Jeon; Jing Han; Paul Plummer; Catherine M Logue; Qijing Zhang
Journal:  Future Microbiol       Date:  2009-03       Impact factor: 3.165

2.  Identification and antimicrobial resistance of campylobacter species isolated from animal sources.

Authors:  Ioanna Marinou; Sotiris Bersimis; Anastassios Ioannidis; Chryssoula Nicolaou; Angeliki Mitroussia-Ziouva; Nicholaos John Legakis; Stylianos Chatzipanagiotou
Journal:  Front Microbiol       Date:  2012-02-24       Impact factor: 5.640

3.  Detection of Campylobacter jejuni and Salmonella typhimurium in chicken using PCR for virulence factor hipO and invA genes (Saudi Arabia).

Authors:  Khaloud M Alarjani; Manal F Elkhadragy; Abdulrahman H Al-Masoud; Hany M Yehia
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.